Ethnic variation of thiopurine S-methyltransferase activity:: a large, prospective population study

被引:40
作者
Cooper, Sheldon C. [1 ]
Ford, Loretta T. [2 ]
Berg, Jonathan D. [2 ]
Lewis, Matthew J. V. [1 ]
机构
[1] City Hosp, Sandwell & W Birmingham NHS Trust, Dept Gastroenterol, Birmingham, W Midlands, England
[2] City Hosp, Sandwell & W Birmingham NHS Trust, Dept Clin Biochem, Birmingham, W Midlands, England
关键词
azathioprine; ethnic variation; mercaptopurine; population; sex; TPMT;
D O I
10.2217/14622416.9.3.303
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The use of azathioprine (and its metabolite mercaptopurine) is limited by toxicity, especially myelosuppression, which is related to activity of the enzyme thiopurine S-methyltransferase (TPMT). TPMT activity varies between individuals and is considered deficient in one in 300 cases. Aims & methods: We identified TPMT activity within an ethnically diverse population of patients attending an inner-city hospital phlebotomy service. A total of 1000 subjects were recruited and analyzed with respect to age, sex and ethnicity. Results: Samples were analyzed from 456 Caucasians, 342 South Asians and 180 Afro-Caribbeans. Six subjects had deficient TPMT activity (0.6%: four women, two men; four Caucasians, one Afro-Caribbean, one South Asian). TPMT activity (nmol 6-methylthioguanine (6-MTG)/gHb/h) ranged 0-76 (median [interquartile range]: 33 [28-39]). Enzyme activity was lower in Afro-Caribbeans (30 [25-37.5]) than Caucasians (34 [29-40]) and South Asians (33 [29-38]), which was significant after adjustment for age and sex (p < 0.0001). Activity was lower in women (p = 0.022), especially South Asian females (n = 194; 32 [28-36]), compared with (35 [30-40]) in men (n = 148; p = 0.002). Conclusions: A higher prevalence of TPMT deficiency was recorded than in previous studies. Afro-Caribbeans have lower activity than Caucasians and South Asians. TPMT enzyme activity was lower among females, especially in South Asians.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 38 条
[1]
Thiopurine methyltransferase alleles in British and Ghanaian populations [J].
Ameyaw, MM ;
Collie-Duguid, ESR ;
Powrie, RH ;
Ofori-Adjei, D ;
McLeod, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (02) :367-370
[2]
Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives [J].
Anglicheau, D ;
Legendre, C ;
Thervet, E .
TRANSPLANTATION, 2004, 78 (03) :311-315
[3]
Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease [J].
Ansari, A ;
Hassan, C ;
Duley, J ;
Marinaki, A ;
Shobowale-Bakre, EM ;
Seed, P ;
Meenan, J ;
Yim, A ;
Sanderson, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) :1743-1750
[4]
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine [J].
Black, AJ ;
McLeod, HL ;
Capell, HA ;
Powrie, RH ;
Matowe, LK ;
Pritchard, SC ;
Collie-Duguid, ESR ;
Reid, DM .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) :716-718
[5]
Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine [J].
Campbell, S ;
Kingstone, K ;
Ghosh, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) :389-398
[6]
Chu E, 1994, Cancer Chemother Biol Response Modif, V15, P1
[7]
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations [J].
Collie-Duguid, ESR ;
Pritchard, SC ;
Powrie, RH ;
Sludden, J ;
Collier, DA ;
Li, T ;
McLeod, HL .
PHARMACOGENETICS, 1999, 9 (01) :37-42
[8]
BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE [J].
CONNELL, WR ;
KAMM, MA ;
RITCHIE, JK ;
LENNARDJONES, JE .
GUT, 1993, 34 (08) :1081-1085
[9]
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [J].
Dubinsky, MC ;
Reyes, E ;
Ofman, J ;
Chiou, CF ;
Wade, S ;
Sandborn, WJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (10) :2239-2247
[10]
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine [J].
Evans, WE ;
Hon, YY ;
Bomgaars, L ;
Coutre, S ;
Holdsworth, M ;
Janco, R ;
Kalwinsky, D ;
Keller, F ;
Khatib, Z ;
Margolin, J ;
Murray, J ;
Quinn, J ;
Ravindranath, Y ;
Ritchey, K ;
Roberts, W ;
Rogers, ZR ;
Schiff, D ;
Steuber, C ;
Tucci, F ;
Kornegay, N ;
Krynetski, EY ;
Relling, MV .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2293-2301